Loading...
XJPX
2370
Market cap42mUSD
Jul 10, Last price  
25.00JPY
1D
0.00%
1Q
-13.79%
Jan 2017
-82.01%
IPO
-99.80%
Name

Medinet Co Ltd

Chart & Performance

D1W1MN
XJPX:2370 chart
P/E
—
P/S
8.61
EPS
—
Div Yield, %
—
Shrs. gr., 5y
14.25%
Rev. gr., 5y
0.69%
Revenues
810m
+5.44%
1,526,000,0001,606,000,0001,838,000,0002,900,215,0003,202,490,0002,674,190,0002,190,986,0002,110,453,0001,843,995,0001,674,379,0001,909,324,0001,704,004,000998,278,0001,059,021,000783,035,000683,033,000633,672,000661,543,000768,501,000810,291,000
Net income
-1.36b
L+6.67%
-821,000,000100,000,000-1,702,000,000245,873,000438,556,000-542,527,000-624,988,000-348,419,000-1,580,722,000-1,712,320,000-1,643,198,000-2,603,685,000-3,048,545,000-795,307,000-842,013,000-843,396,000-1,254,092,000-1,437,950,000-1,276,994,000-1,362,138,000
CFO
-1.41b
L+18.44%
-642,000,000-851,000,000-626,000,000318,294,000528,004,000-251,574,000-337,538,000-516,010,000-1,020,104,000-1,567,375,000-1,088,096,000-1,333,145,000-2,499,487,000-917,110,000-547,542,000-612,075,000-1,131,080,000-1,258,294,000-1,193,337,000-1,413,360,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Established in 1995 and headquartered in Tokyo, Japan, MEDINET Co., Ltd. functions as a contract development and manufacturing organization (CDMO) primarily focused on regenerative medicine and cell therapy solutions within Japan. The company furnishes comprehensive support for immuno-cell therapy, encompassing critical elements such as specialized technical expertise, advanced facilities, robust operational systems, essential materials, and skilled cell engineers. Furthermore, MEDINET actively manufactures regenerative medical products, investigational cell products, and other specified cell-based therapies. Its extensive value chain offerings also cover personnel training, facility and equipment design, operational management, standard operating procedure (SOP) preparation, logistics networks, information systems, purchasing and production management, stringent quality management and assurance, and technology transfer and process development. The firm actively collaborates with and supports medical institutions, research organizations, and biopharmaceutical companies in their endeavors to advance immuno-cell therapy.
URL
https://www.medinet-inc.co.jp/
IPO date
Oct 08, 2003
Employees
92
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑092024‑092023‑092022‑092021‑092020‑092019‑092018‑092017‑092016‑09
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT